Andreas Varkaris, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proto-Oncogene Proteins c-met | 3 | 2015 | 578 | 1.030 |
Why?
|
src-Family Kinases | 3 | 2014 | 549 | 0.860 |
Why?
|
Prostatic Neoplasms | 13 | 2023 | 10999 | 0.760 |
Why?
|
Hyperinsulinism | 1 | 2024 | 415 | 0.750 |
Why?
|
Receptors, Androgen | 3 | 2023 | 1049 | 0.750 |
Why?
|
Phenylthiohydantoin | 1 | 2019 | 190 | 0.640 |
Why?
|
Radium | 1 | 2016 | 65 | 0.560 |
Why?
|
Interleukin-8 | 1 | 2019 | 685 | 0.540 |
Why?
|
Anilides | 3 | 2021 | 405 | 0.490 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2933 | 0.480 |
Why?
|
Receptor, IGF Type 1 | 2 | 2013 | 390 | 0.470 |
Why?
|
Hepatocyte Growth Factor | 2 | 2013 | 270 | 0.470 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 545 | 0.430 |
Why?
|
Interleukin-6 | 2 | 2019 | 3194 | 0.380 |
Why?
|
Insulin-Like Growth Factor I | 3 | 2013 | 2015 | 0.370 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2019 | 3504 | 0.360 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2024 | 888 | 0.350 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1045 | 0.330 |
Why?
|
Carcinoma, Renal Cell | 2 | 2021 | 3101 | 0.320 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2017 | 3562 | 0.290 |
Why?
|
Kidney Neoplasms | 2 | 2021 | 4189 | 0.290 |
Why?
|
Liver Transplantation | 1 | 2017 | 2110 | 0.280 |
Why?
|
Breast Neoplasms | 2 | 2024 | 20676 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 4 | 2020 | 5502 | 0.280 |
Why?
|
Pyridines | 3 | 2021 | 2810 | 0.270 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 2185 | 0.260 |
Why?
|
MicroRNAs | 2 | 2019 | 3712 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5154 | 0.230 |
Why?
|
Prostate | 1 | 2011 | 1743 | 0.220 |
Why?
|
Bone Neoplasms | 4 | 2016 | 2521 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9122 | 0.220 |
Why?
|
Antineoplastic Agents | 7 | 2020 | 13635 | 0.210 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6726 | 0.210 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4216 | 0.210 |
Why?
|
Brain Neoplasms | 2 | 2021 | 8791 | 0.200 |
Why?
|
Signal Transduction | 8 | 2023 | 23355 | 0.200 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 3485 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11410 | 0.190 |
Why?
|
Cryoelectron Microscopy | 1 | 2024 | 567 | 0.190 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2727 | 0.180 |
Why?
|
Fatal Outcome | 3 | 2020 | 1850 | 0.180 |
Why?
|
Inflammation | 1 | 2019 | 10534 | 0.170 |
Why?
|
Orchiectomy | 2 | 2011 | 462 | 0.170 |
Why?
|
Phosphorylation | 5 | 2023 | 8416 | 0.160 |
Why?
|
Hypernatremia | 1 | 2018 | 82 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2020 | 12985 | 0.160 |
Why?
|
Male | 24 | 2023 | 349022 | 0.150 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4832 | 0.150 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2020 | 2936 | 0.150 |
Why?
|
Progesterone | 1 | 2022 | 772 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-yes | 1 | 2015 | 16 | 0.130 |
Why?
|
Hyponatremia | 1 | 2018 | 296 | 0.130 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 384 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2015 | 618 | 0.130 |
Why?
|
Cell Line, Tumor | 7 | 2020 | 16646 | 0.130 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2015 | 120 | 0.130 |
Why?
|
Humans | 29 | 2024 | 739398 | 0.130 |
Why?
|
Chitosan | 1 | 2015 | 135 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 946 | 0.120 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 250 | 0.120 |
Why?
|
Benzamides | 1 | 2019 | 1374 | 0.120 |
Why?
|
Pyrazoles | 2 | 2022 | 1963 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 1431 | 0.110 |
Why?
|
Sodium | 1 | 2018 | 1625 | 0.110 |
Why?
|
Ossification, Heterotopic | 1 | 2015 | 238 | 0.110 |
Why?
|
Tumor Burden | 2 | 2015 | 1904 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2019 | 8400 | 0.110 |
Why?
|
Apoptosis | 4 | 2020 | 9714 | 0.100 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2013 | 413 | 0.100 |
Why?
|
Taxoids | 2 | 2013 | 661 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1849 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 5148 | 0.090 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1654 | 0.090 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 1583 | 0.090 |
Why?
|
Gene Transfer Techniques | 1 | 2015 | 1227 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 2897 | 0.090 |
Why?
|
DNA | 1 | 2024 | 7275 | 0.090 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2084 | 0.080 |
Why?
|
Bone Diseases | 1 | 2012 | 417 | 0.080 |
Why?
|
Drug Design | 2 | 2011 | 1088 | 0.080 |
Why?
|
Receptor, Insulin | 1 | 2012 | 845 | 0.080 |
Why?
|
Aged | 8 | 2020 | 162698 | 0.080 |
Why?
|
Prognosis | 2 | 2019 | 28901 | 0.080 |
Why?
|
Integrins | 1 | 2013 | 845 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6871 | 0.080 |
Why?
|
RNA Interference | 2 | 2015 | 2899 | 0.080 |
Why?
|
Autophagy | 1 | 2015 | 1295 | 0.080 |
Why?
|
Heart Diseases | 1 | 2020 | 2782 | 0.080 |
Why?
|
Mice, Nude | 4 | 2015 | 3692 | 0.080 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18003 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8307 | 0.070 |
Why?
|
Enzyme Activation | 1 | 2013 | 3701 | 0.070 |
Why?
|
Female | 10 | 2024 | 378853 | 0.070 |
Why?
|
Mice | 8 | 2023 | 81002 | 0.070 |
Why?
|
Animals | 11 | 2023 | 168368 | 0.070 |
Why?
|
Ligands | 1 | 2013 | 3311 | 0.070 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3517 | 0.070 |
Why?
|
Survival Rate | 1 | 2019 | 12761 | 0.070 |
Why?
|
Bone and Bones | 1 | 2015 | 2575 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4014 | 0.060 |
Why?
|
Cell Movement | 2 | 2015 | 5221 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2017 | 10961 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2639 | 0.060 |
Why?
|
Nanoparticles | 1 | 2015 | 1906 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 3498 | 0.060 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2023 | 42 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7862 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9812 | 0.060 |
Why?
|
Protein Binding | 1 | 2014 | 9375 | 0.050 |
Why?
|
Cell Proliferation | 5 | 2015 | 10455 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8274 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2019 | 38942 | 0.040 |
Why?
|
Mutation | 1 | 2024 | 29658 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6361 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7709 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2011 | 7897 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 13872 | 0.040 |
Why?
|
Mitosis | 1 | 2023 | 1212 | 0.040 |
Why?
|
Transfection | 2 | 2015 | 5884 | 0.040 |
Why?
|
Ubiquitination | 1 | 2020 | 1003 | 0.030 |
Why?
|
Thiazoles | 2 | 2013 | 1488 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3863 | 0.030 |
Why?
|
Androgens | 1 | 2023 | 1270 | 0.030 |
Why?
|
Disease Progression | 1 | 2011 | 13237 | 0.030 |
Why?
|
Middle Aged | 5 | 2020 | 212863 | 0.030 |
Why?
|
X-Ray Microtomography | 1 | 2015 | 426 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2020 | 1405 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2013 | 315 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2015 | 62693 | 0.020 |
Why?
|
3T3 Cells | 1 | 2013 | 1103 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 21507 | 0.020 |
Why?
|
Prostate-Specific Antigen | 2 | 2011 | 2441 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2009 | 5147 | 0.020 |
Why?
|
Up-Regulation | 1 | 2020 | 4205 | 0.020 |
Why?
|
Triazines | 1 | 2012 | 316 | 0.020 |
Why?
|
Pyrimidines | 2 | 2013 | 2918 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2012 | 903 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4743 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57650 | 0.020 |
Why?
|
Osteoblasts | 1 | 2013 | 1163 | 0.020 |
Why?
|
Mitochondria | 1 | 2020 | 3522 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10362 | 0.020 |
Why?
|
Prednisone | 1 | 2011 | 1560 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2270 | 0.020 |
Why?
|
Critical Illness | 1 | 2018 | 2656 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2018 | 3672 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 5181 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2012 | 6310 | 0.020 |
Why?
|
Cell Cycle | 1 | 2012 | 2960 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 2507 | 0.010 |
Why?
|
Administration, Oral | 1 | 2011 | 3909 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 4935 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15036 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6478 | 0.010 |
Why?
|
Prostatectomy | 1 | 2011 | 1858 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2015 | 11347 | 0.010 |
Why?
|
Time Factors | 2 | 2015 | 40050 | 0.010 |
Why?
|
NF-kappa B | 1 | 2009 | 2502 | 0.010 |
Why?
|
Weight Loss | 1 | 2011 | 2589 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 40389 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8605 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 76631 | 0.010 |
Why?
|
Cell Survival | 1 | 2009 | 5877 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 3802 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53037 | 0.010 |
Why?
|
Pain | 1 | 2011 | 4923 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 56255 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9259 | 0.010 |
Why?
|
Quality of Life | 1 | 2011 | 12640 | 0.010 |
Why?
|
Adult | 1 | 2018 | 213394 | 0.000 |
Why?
|